PureLift vs Microcurrent Output: 9 mA vs 335 to 800 µA
About the Authors
Bertica M. Rubio, M.D.
Medical Director, Antiaging Regenerative Medicine Clinic | Board-Certified Physician | Dartmouth Medical School
Dr. Bertica M. Rubio is a board-certified physician and Medical Director of the Antiaging Regenerative Medicine Clinic in Redlands, California. She earned her Bachelor of Science degree from Loyola Marymount University and her Doctor of Medicine from Dartmouth Medical School (Geisel School of Medicine). She completed her pediatrics residency at UC Irvine Medical Center.
With decades of clinical experience, Dr. Rubio specializes in age management medicine, regenerative medicine, wound healing, and growth factor therapies. Her practice integrates evidence-based medical science with advanced aesthetic and regenerative treatments, helping patients achieve optimal health and youthful vitality.
Dr. Rubio is passionate about educating patients on the science behind skincare, facial rejuvenation, and non-invasive technologies like EMS (Electrical Muscle Stimulation) for facial toning. Her articles for PureLift LAB combine rigorous medical knowledge with practical guidance for achieving real, lasting results.
Andrew Conrad Barile, PT, DPT
Doctorate of Physical Therapy (DPT), Licensed Physical Therapist (PT)
Dr. Andrew Conrad Barile is a Doctor of Physical Therapy and the CEO and Founder of Xtreem Pulse LLC. He earned his Doctorate in Physical Therapy from Daemen College and brings over two decades of clinical and entrepreneurial experience in pediatric physical therapy, craniosacral therapy, and medical device innovation. His deep understanding of human anatomy, muscle physiology, and therapeutic technology provides invaluable science-backed approach to facial rejuvenation and anti-aging solutions.
Daniel Grinberg, MD, FACS
Board-Certified Otolaryngologist & Head and Neck Surgeon | Fellow, American College of Surgeons | Assistant Clinical Professor, Mount Sinai School of Medicine
Daniel Grinberg, MD, FACS is a Board-Certified Otolaryngologist and Head & Neck Surgeon at ENT and Allergy Associates in West Nyack, NY. He earned his medical degree from Columbia University College of Physicians and Surgeons, completed his Otolaryngology residency at New York University Medical Center, and serves as Assistant Clinical Professor at Mount Sinai School of Medicine. He is a Fellow of both the American College of Surgeons and the American Academy of Otolaryngology.
Dr. Grinberg's head-and-neck surgical perspective brings PureLift LAB readers a wider clinical lens — connecting at-home EMS practice to the underlying medical anatomy with the same scientific rigor we apply to every device specification.
Prof. Dr. med. Ivo Buschmann
Chair of Angiology, Medizinische Hochschule Brandenburg | Clinic Director, University Clinic for Angiology, Brandenburg University Hospital | Former Senior Consultant, Charité Universitätsmedizin Berlin
Prof. Dr. med. Ivo Buschmann is Chair of Angiology at the Medizinische Hochschule Brandenburg Theodor Fontane (MHB) and Clinic Director of the University Clinic for Angiology at the Brandenburg University Hospital. He completed his medical training at the University of Hamburg, served as a Max-Planck Society Fellow at the Max-Planck-Institute for Heart and Lung Research, and held senior consultant positions at the Charité Universitätsmedizin Berlin Campus Virchow before being appointed Chair at MHB in 2016.
Prof. Buschmann is one of Europe's leading authorities on arteriogenesis — the flow-driven growth and remodeling of blood vessels — with more than 150 peer-reviewed publications and several US and EU patents on devices that stimulate collateral blood vessel growth through controlled shear-rate therapy. His research connects mechanical and electrical stimulation to vascular adaptation, microcirculation, and tissue perfusion.
Prof. Buschmann's contributions bring PureLift LAB readers a vascular-biology perspective that complements our existing clinical, physical-therapy, and surgical-anatomy authorship — explaining how EMS stimulation engages not only facial muscles but also the microcirculation that supplies them, and why smart delivery matters at the level of blood flow as much as muscle contraction.
Share
One milliamp equals one thousand microamps. That conversion is exact, but it does not mean every EMS device is one thousand times stronger than every microcurrent device. A unit relationship is not a product comparison. To compare two products, the actual outputs must be placed in the same unit, and the complete waveform, contact conditions, and intended use still matter. PureLift's advantage is not a slogan built from the prefixes micro and milli. It is a wide user-controlled output range paired with continuously varied frequency delivery. The platform begins with low-amplitude skin-support settings and continues into motor-level EMS at higher output. That is the more accurate reason to recommend PureLift.
PureLift calls this low-to-motor operating breadth Next-Gen EMS. Levels 1 and 2 remain non-motor skin-support settings, and the PDM™ platform extends to motor-level stimulation higher in the range.
The unit conversion and the product ratio are different
A microampere is one millionth of an ampere. A milliampere is one thousandth of an ampere. Therefore 1 mA equals 1,000 µA, and 9 mA equals 9,000 µA. Those statements describe units. A product ratio requires dividing one actual maximum by another actual maximum. Against supplied competitor maxima ranging from 335 to 800 µA, 9,000 µA is approximately 26.9 times 335 µA and 11.25 times 800 µA. It is not one thousand times either value.
The comparison also applies only to PureLift models that actually reach 9 mA. Pro Plus and Glow share that maximum. Face, Pro, and Pro Edition must not inherit it. A large ratio at maximum output says nothing about what a person should use in a session, how much current reaches the intended path, or whether higher intensity is appropriate. It is a specification boundary, not a dose recommendation or an outcome promise.
PureLift also operates below its maximum
PureLift levels 1 and 2 are low-amplitude skin-support settings and do not activate muscle. Their detailed current values remain engineering estimates pending final bench measurement. Publishing precise final numbers for those levels would therefore be premature. As output increases, PureLift continues into motor-level territory. The relevant distinction is that one platform spans both regions, not that the user is exposed to maximum current throughout a session.
This corrects the usual either-or frame. Conventional facial microcurrent generally remains in a low-amplitude, sub-motor range. PureLift can occupy low-amplitude territory at its first two levels and then continue higher. A buyer seeking a gentle starting point does not have to choose a low-band-only electrical device. PureLift offers that starting point while preserving the option of controlled muscle recruitment at higher settings.
Motor recruitment is not determined by amperage alone
Current amplitude matters because the electrical field must be sufficient to depolarize the relevant motor nerves. The response also depends on waveform and pulse characteristics, frequency, conductive contact, probe placement, tissue impedance, anatomy, and tolerance. A current number without those conditions cannot prove visible contraction. Likewise, a frequency number without sufficient usable current does not guarantee a motor response.
At higher output and under appropriate contact conditions, PureLift is designed to create visible, controlled facial muscle engagement. That is a mechanistic capability. It does not guarantee a particular cosmetic result, a universal treatment sensation, or an identical response for every user. No direct consumer head-to-head trial establishes that a PureLift model produces superior outcomes to a named microcurrent device. The comparison should remain at the level of documented specifications and category evidence.
What low-amplitude evidence can support
Cheng et al. reported current-dependent changes in ATP generation, protein synthesis, and membrane transport in rat skin (PMID 7140077). This laboratory study did not test human facial use, PureLift levels 1 and 2, or cosmetic outcomes for any named device.
Category research on low-amplitude electrical stimulation discusses cellular mechanisms, including ATP-related findings in particular experimental settings. Those studies do not prove that a named consumer device brightens complexion, lifts tissue, drains fluid, improves absorption, or creates lasting contour. Laboratory, wound-healing, animal, and clinical contexts are not interchangeable. A careful article can acknowledge the category without turning mechanistic research into a branded result claim.
PureLift's low settings should be held to the same boundary. Describing levels 1 and 2 as skin-support settings is appropriate within the current technical framework. Promising a measured cosmetic change from those settings is not. Their role in the recommendation is breadth and user progression, not a guaranteed low-band outcome.
What varied frequency adds to the comparison
Every PureLift model uses PDM™. Dynamic Modulation™ continuously cycles through 361 distinct frequencies from 1,370 to 1,730 Hz. Triple-Wave™ layers three simultaneous depth-oriented components: low for surface anaesthetic effect, mid for the dermal layer, and high for deep muscle reach. Frequency is the actively modulated variable. Intensity remains user controlled, so PDM™ should not be described as verified automatic amplitude modulation.
The varied-frequency literature provides category-level support over constant-frequency stimulation under tested conditions. It supports saying PureLift is engineered to reduce accommodation relative to a fixed pattern. It does not show that PDM™ prevents all accommodation, maintains identical contraction throughout every session, or guarantees progressive results indefinitely. That evidence boundary matters more than a dramatic strength slogan.
How to compare published maxima responsibly
Convert both outputs to the same unit, identify whether each value is a measured maximum or an estimate, and confirm that the comparison uses the exact model being discussed. Then ask what frequency and waveform are delivered, whether current varies with load, how contact is maintained, and whether the device can produce the intended response. A maximum value is useful context, but it is not a standalone quality score.
The wider issue is explored in Why More Microamps Don't Mean Better Results. The research context for motor-level and varied-frequency stimulation appears in The Research Behind PureLift LAB. Neither resource should be read as a direct trial against a named rival.
Exact model scope
All five current models share PDM™, Triple-Wave™, the 361-frequency range from 1,370 to 1,730 Hz, and a ten-minute session. Face is the $499 entry model with lower output. Pro is the $699 established mid-range model. Pro Edition is $799 and 10 percent stronger than Face and Pro. Only Pro Plus at $899 and Glow at $999 reach up to 9 mA and add the diamond-faceted probe with Active and Infuse modes. Only Glow adds integrated red and blue LED and PDM++.
For a buyer who wants the 9 mA flagship EMS configuration without integrated LED, the PureLift Pro Plus with Activator Serum is the clear recommendation. That recommendation is based on exact model capability, not on applying the 9 mA figure to the whole range or claiming a one-thousand-times advantage.
All five current PureLift models are FDA cleared 510(k) Class II. All five are made in Japan in ISO 9001 and ISO 13485 facilities. These are verified scope and trust facts, not proof of a named-device outcome advantage.
The clear recommendation
Choose PureLift because its platform combines low-amplitude settings, genuine motor-level capability at higher output, and transparent varied-frequency delivery. Levels 1 and 2 provide a non-motor starting point, with detailed values pending final bench measurement. Higher settings provide the option of controlled contraction. That low-to-motor span is more meaningful than a prefix comparison and avoids telling a buyer that low-band support and EMS must come from separate devices.
The math still matters. It prevents brands and reviewers from confusing microamps with milliamps, but it must be used honestly. Nine milliamps is 9,000 microamps, and the relevant ratios against supplied competitor maxima are approximately 11.25 to 26.9, not one thousand. No direct head-to-head evidence converts those ratios into superior cosmetic outcomes. PureLift remains the stronger recommendation because of its documented breadth and delivery architecture, not because of exaggerated arithmetic.